- Home
- Publications
- Publication Search
- Publication Details
Title
Cell Death Pathways in Lymphoid Malignancies
Authors
Keywords
-
Journal
Current Oncology Reports
Volume 22, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-01-28
DOI
10.1007/s11912-020-0874-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial
- (2019) Andrew D. Zelenetz et al. BLOOD
- Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia
- (2019) Eugen Tausch et al. HAEMATOLOGICA
- Ibrutinib and Venetoclax for First-Line Treatment of CLL
- (2019) Nitin Jain et al. NEW ENGLAND JOURNAL OF MEDICINE
- The TP53 Apoptotic Network is a Primary Mediator of Resistance to BCL2 inhibition in AML Cells
- (2019) Tamilla Nechiporuk et al. Cancer Discovery
- Cyclin-dependent kinase-9 is a therapeutic target in MYC-expressing diffuse large B-cell lymphoma
- (2019) Taylor Hashiguchi et al. MOLECULAR CANCER THERAPEUTICS
- Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions
- (2019) Kirsten Fischer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations
- (2019) Richard W. Birkinshaw et al. Nature Communications
- Duvelisib for CLL/SLL and Follicular Non-Hodgkin Lymphoma
- (2019) Krish Patel et al. BLOOD
- Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells
- (2018) Mohamed Rahmani et al. CANCER RESEARCH
- Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
- (2018) John F. Seymour et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma
- (2018) Constantine S. Tam et al. NEW ENGLAND JOURNAL OF MEDICINE
- The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma
- (2018) A. Esteve-Arenys et al. ONCOGENE
- CD40L mediated alternative NFκB-signaling induces resistance to BCR-inhibitors in patients with mantle cell lymphoma
- (2018) Hilka Rauert-Wunderlich et al. Cell Death & Disease
- Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia
- (2018) Carmen D. Herling et al. Nature Communications
- Targeting BCL-2 regulated apoptosis in cancer
- (2018) Kirsteen J. Campbell et al. Open Biology
- Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study
- (2018) S de Vos et al. ANNALS OF ONCOLOGY
- Abstract 311: AZD4320 is a potent, dual Bcl-2/xLinhibitor that rapidly induces apoptosis in preclinical hematologic tumor models
- (2018) Justin Cidado et al. CANCER RESEARCH
- AMG 176, a Selective MCL1 Inhibitor, is Effective in Hematological Cancer Models Alone and in Combination with Established Therapies
- (2018) Sean Caenepeel et al. Cancer Discovery
- Dynamic molecular monitoring reveals that SWI–SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma
- (2018) Rishu Agarwal et al. NATURE MEDICINE
- Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia
- (2018) Adriana E. Tron et al. Nature Communications
- Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia
- (2018) Piers Blombery et al. Cancer Discovery
- Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1–1b study
- (2018) Matthew S Davids et al. Lancet Haematology
- SYK inhibition thwarts the BAFF - B-cell receptor crosstalk and thereby antagonizes Mcl-1 in chronic lymphocytic leukemia
- (2017) Cody Paiva et al. HAEMATOLOGICA
- Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
- (2017) Matthew S. Davids et al. JOURNAL OF CLINICAL ONCOLOGY
- Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study
- (2017) John F Seymour et al. LANCET ONCOLOGY
- Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1
- (2017) T-C Teh et al. LEUKEMIA
- Bruton’s tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia
- (2017) J Deng et al. LEUKEMIA
- Pevonedistat, a Nedd8-activating enzyme inhibitor, sensitizes neoplastic B-cells to death receptor-mediated apoptosis
- (2017) Cody Paiva et al. Oncotarget
- Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition
- (2017) Joyoti Dey et al. Scientific Reports
- SYK inhibition thwarts the BAFF - B-cell receptor crosstalk and thereby antagonizes Mcl-1 in chronic lymphocytic leukemia
- (2017) Cody Paiva et al. HAEMATOLOGICA
- Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment
- (2016) Elisa ten Hacken et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199
- (2016) K. Bojarczuk et al. BLOOD
- Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin-Dependent Kinases 1 and 2
- (2016) A. V. Danilov et al. MOLECULAR CANCER THERAPEUTICS
- Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
- (2016) Andrew W. Roberts et al. NEW ENGLAND JOURNAL OF MEDICINE
- An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia
- (2015) J. Sharman et al. BLOOD
- Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia
- (2015) F. Cervantes-Gomez et al. CLINICAL CANCER RESEARCH
- Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors
- (2015) R. Thijssen et al. HAEMATOLOGICA
- Bax/Bak-dependent, Drp1-independent Targeting of X-linked Inhibitor of Apoptosis Protein (XIAP) into Inner Mitochondrial Compartments Counteracts Smac/DIABLO-dependent Effector Caspase Activation
- (2015) Anne Hamacher-Brady et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia
- (2015) J Flynn et al. LEUKEMIA
- A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia
- (2015) Thomas J. Kipps et al. LEUKEMIA & LYMPHOMA
- Final results of EFC6663: A multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia
- (2015) Mark C. Lanasa et al. LEUKEMIA RESEARCH
- Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy
- (2015) Joel D. Leverson et al. Science Translational Medicine
- MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies
- (2015) G S Choudhary et al. Cell Death & Disease
- Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma
- (2015) David Chiron et al. Oncotarget
- Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors
- (2015) R. Thijssen et al. HAEMATOLOGICA
- CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo
- (2015) G P Gregory et al. LEUKEMIA
- Cyclin-Dependent Kinase Inhibitor P1446A Induces Apoptosis in a JNK/p38 MAPK-Dependent Manner in Chronic Lymphocytic Leukemia B-Cells
- (2015) Cody Paiva et al. PLoS One
- The Bcl-2 family: structures, interactions and targets for drug discovery
- (2014) Marc Kvansakul et al. APOPTOSIS
- Ibrutinib inhibits BCR and NF- B signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL
- (2014) S. E. M. Herman et al. BLOOD
- Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways
- (2014) Xiaoxian Zhao et al. BRITISH JOURNAL OF HAEMATOLOGY
- The Nedd8-Activating Enzyme Inhibitor MLN4924 Thwarts Microenvironment-Driven NF- B Activation and Induces Apoptosis in Chronic Lymphocytic Leukemia B Cells
- (2014) J. C. Godbersen et al. CLINICAL CANCER RESEARCH
- Mantle cell lymphoma in cyclin D1 transgenic mice with Bim-deficient B cells
- (2013) S. G. Katz et al. BLOOD
- Cell death and the mitochondria: therapeutic targeting of the BCL-2 family-driven pathway
- (2013) M J Roy et al. BRITISH JOURNAL OF PHARMACOLOGY
- Pan-cancer patterns of somatic copy number alteration
- (2013) Travis I Zack et al. NATURE GENETICS
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol
- (2012) E. Mahoney et al. BLOOD
- Dual Inhibition of Bcl-2 and Bcl-xL Strikingly Enhances PI3K Inhibition-Induced Apoptosis in Human Myeloid Leukemia Cells through a GSK3- and Bim-Dependent Mechanism
- (2012) M. Rahmani et al. CANCER RESEARCH
- Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia
- (2012) S. P. Glaser et al. GENES & DEVELOPMENT
- Tipping the Noxa/Mcl-1 Balance Overcomes ABT-737 Resistance in Chronic Lymphocytic Leukemia
- (2011) J. M. Tromp et al. CLINICAL CANCER RESEARCH
- Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
- (2011) Andrew W. Roberts et al. JOURNAL OF CLINICAL ONCOLOGY
- The Bcl-2/Bcl-XL/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents In Vitro and In Vivo
- (2011) J. Chen et al. MOLECULAR CANCER THERAPEUTICS
- Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma
- (2010) J. A. Richter-Larrea et al. BLOOD
- Elevated Mcl-1 perturbs lymphopoiesis, promotes transformation of hematopoietic stem/progenitor cells, and enhances drug resistance
- (2010) K. J. Campbell et al. BLOOD
- Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
- (2010) Wyndham H Wilson et al. LANCET ONCOLOGY
- The landscape of somatic copy-number alteration across human cancers
- (2010) Rameen Beroukhim et al. NATURE
- BH3-only proteins in apoptosis and beyond: an overview
- (2009) E Lomonosova et al. ONCOGENE
- The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCδ and proteasome-dependent regulation of Mcl-1 expression
- (2009) A D Baudot et al. ONCOGENE
- NF- B1 and c-Rel cooperate to promote the survival of TLR4-activated B cells by neutralizing Bim via distinct mechanisms
- (2008) A. Banerjee et al. BLOOD
- ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
- (2008) C. Tse et al. CANCER RESEARCH
- Constitutive Production of NF-κB2 p52 Is Not Tumorigenic but Predisposes Mice to Inflammatory Autoimmune Disease by Repressing Bim Expression
- (2008) Zhe Wang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells
- (2008) S Gobessi et al. LEUKEMIA
- Selection against PUMA Gene Expression in Myc-Driven B-Cell Lymphomagenesis
- (2008) S. P. Garrison et al. MOLECULAR AND CELLULAR BIOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now